The European Commission last week promised tougher scrutiny of drug industry deals that maximize profits on branded medicines by slowing consumers' access to cheap generic drugs.rnIt opened an investigation into Servier, a pharmaceutical company headquartered in Neuilly-sur-Seine, France, and several other drug manufacturers, over agreements that may have breached anti-trust laws.
展开▼
